Cardiomyocytes actively proliferate during embryogenesis and withdraw from the cell cycle during neonatal stages. FOXO (Forkhead O) transcription factors are a direct target of phosphatidylinositol-3 kinase/AKT signaling in skeletal and smooth muscle and regulate expression of the Cip/Kip family of cyclin kinase inhibitors in other cell types; however, the interaction of phosphatidylinositol-3 kinase/AKT signaling, FOXO transcription factors, and cyclin kinase inhibitor expression has not been reported for the developing heart. Here, we show that FOXO1 and FOXO3 are expressed in the developing myocardium concomitant with increased cyclin kinase inhibitor expression from embryonic to neonatal stages. Cell culture studies show that embryonic cardiomyocytes are responsive to insulin-like growth factor 1 stimulation, which results in the induction of the phosphatidylinositol-3 kinase/AKT pathway, cytoplasmic localization of FOXO proteins, and increased myocyte proliferation. Likewise, adenoviral-mediated expression of AKT promotes cardiomyocyte proliferation and cytoplasmic localization of FOXO. In contrast, increased expression of FOXO1 negatively affects myocyte proliferation. In vivo myocyte-specific transgenic expression of FOXO1 during heart development causes embryonic lethality at embryonic day 10.5 because of severe myocardial defects that coincide with premature activation of p21 cip1 , p27 kip1 , and p57 kip2 and decreased myocyte proliferation. Transgenic expression of dominant negative FOXO1 in cardiomyocytes does not obviously affect heart development at embryonic day 10.5, but results in abnormal morphology of the myocardium by embryonic day 18.5 along with decreased cyclin kinase inhibitor expression and increased myocyte proliferation. These data support FOXO transcription factors as negative regulators of cardiomyocyte proliferation and promoters of neonatal cell cycle withdrawal during heart development. (Circ Res. 2008;102:686-694.) Key Words: heart development Ⅲ FOXO1 (FKHR) Ⅲ Cip/Kip cyclin kinase inhibitors Original
N ormal heart morphogenesis and development are dependent on highly controlled differential regulation of cell proliferation in specific populations of cardiomyocytes during embryonic, fetal, and neonatal stages. 1 Embryonic cardiomyocytes throughout the primitive heart tube rapidly proliferate to provide sufficient cell numbers to build the working myocardium. 2 At fetal stages, proper formation of the ventricular trabeculae, compact zone, and interventricular septum is dependent on more localized temporal and spatial regulation of cardiomyocyte proliferation. 3, 4 Immediately before birth, cardiomyocytes throughout the myocardium undergo a hyperplastic to hypertrophic transition in which cell division slows and cell growth increases. 5 After birth, neonatal cardiomyocytes withdraw from the cell cycle, and growth of the myocardium into adulthood occurs primarily by hypertrophy. 1 The molecular mechanisms that control cardiomyocyte maturation, proliferation, and resultant myocardial growth are fundamental to normal heart development, but they are not yet well defined. Likewise extensive efforts to induce postmitotic cardiomyocytes to reenter the cell cycle have not been very successful. Therefore identification of the signaling pathways, transcriptional effectors, and downstream target genes that control normal cardiomyocyte proliferation during prenatal development and neonatal cell cycle withdrawal could provide new strategies for manipulation of the cardiomyocyte cell cycle in older individuals.
The Forkhead O (FOXO) family of transcription factors has important roles in cell proliferation, metabolism, and aging in a variety of cell types. 6 FOXO1 and FOXO3 have been implicated in the regulation of skeletal and smooth muscle differentiation, cell size regulation and proliferation, but their roles in the developing heart have not been determined. 7 Loss of FOXO1 function in mice leads to embryonic lethality before heart morphogenesis, and mice lacking FOXO3 are apparently normal at birth but develop cardiac hypertrophy and heart failure later in adult life. 8, 9 Therefore, alternative strategies are necessary to determine the functions of FOXO transcription factors in cardiac cell proliferation and growth.
FOXO transcriptional activity is regulated by a variety of signaling mechanisms including phosphatidylinositol-3 kinase (PI3K)-mediated activation of AKT, which directly phosphorylates FOXO at serine 256, leading to nuclear export and inactivation. 6 In the absence of negative regulation by AKT, FOXO factors remain in the nucleus and induce transcription of a variety of downstream target genes that collectively inhibit proliferation and induce cell cycle withdrawal. 6 Direct downstream targets of FOXO1 include the members of Cip/Kip family of cyclin kinase inhibitors (CKIs), p21 CIP1 and p27 KIP1 , which have also been implicated in cardiomyocyte cell cycle withdrawal after birth. 10 -12 However, CKIs can be regulated by multiple mechanisms, and the role of FOXO in their regulation during cardiomyocyte cell cycle withdrawal has not been previously characterized.
Growth factors, including insulin-like growth factor (IGF)1, activate PI3K/AKT signaling in the heart to promote growth of the myocardium during development and after birth. 13, 14 In mice, loss of IGF1 causes hypoplasia of the myocardium and overall retarded growth, 15 whereas cardiacspecific overexpression of IGF1 results in increased number of cardiomyocytes after birth. 16 Genetic deletion of the p110␣ subunit of PI3K causes severe proliferation defects that result in lethality at embryonic day (E)9.5. 17 Likewise, AKT1 and AKT3 double knockout mice display hypoplastic ventricular myocardium, which causes lethality at embryonic day (E)12 to E13. 18 In contrast, increased AKT in the myocardium promotes cardiomyocyte proliferation by extending the postnatal cardiac cell cycle. 19 Thus, cardiomyocyte proliferation is affected by manipulation of multiple signaling components upstream of FOXO factors, which supports a critical role for FOXO function in the regulation of cardiomyocyte proliferation during heart development. However, the intersection of PI3K/AKT signaling with FOXO transcription factors in regulation of cell proliferation in response to growth factors has not been characterized in the developing or neonatal heart.
In this study, we report the expression of FOXO factors in the myocardium during heart development and assess their function downstream of IGF1/PI3K/AKT signaling in cultured primary embryonic cardiomyocytes. Generation of transgenic embryos with cardiomyocyte-specific expression of FOXO1 during heart development provides in vivo evidence of a critical role for FOXO factors in the control of cardiomyocyte proliferation through the regulation of p21 cip1 , p27 kip1 , and p57 kip2 expression. Combined, these data support a mechanism whereby FOXO transcription factors, antagonized by IGF/PI3K/AKT signaling, negatively regulate cardiomyocyte proliferation and myocardial growth via transcriptional regulation of CKIs.
Materials and Methods
Collection of cardiac tissue as well as procedures for RNA isolation and immunostaining were performed as previously described. 20, 21 Embryonic cardiomyocytes were enzymatically dissociated from E14.5 hearts of FVBN mice for primary cultures, 22 which were treated pharmacologically or infected with recombinant adenoviruses expressing FOXO or AKT. Protein lysates for Western blotting were obtained from stage-specific cardiac tissue, as well as cultured primary cardiomyocytes. ␤MHC-FOXO1 transgenic embryos were generated using the ␤-myosin heavy chain (MHC) promoter 23 driving expression of wild-type (WT), constitutively active (CA), or dominant negative (DN) FOXO1. 24 Cardiomyocyte proliferation indices were calculated and quantitative real-time RT-PCR was performed on tissue isolated from hearts of transgenic and nontransgenic control embryos. Chromatin immunoprecipitation of p21 cip1 promoter sequences bound to FOXO1 was performed using embryonic and neonatal cardiomyocyte samples. All animal procedures were approved and performed in accordance with institutional guidelines. An expanded Materials and Methods section is available in the online data supplement at http://circres.ahajournals.org.
Results

FOXO Transcription Factors Are Expressed in the Developing Heart
To determine the developmental expression patterns of FOXO transcription factors in the heart, mRNA and protein expression of FOXO family members was examined at various stages of heart development. Expression of FOXO1 and FOXO3 transcripts was detected by RT-PCR in the developing heart at E11, E15, and neonatal stages ( Figure  1A ). In the adult heart, FOXO1 expression was very low in comparison with earlier stages, whereas the expression of FOXO3 was not observed. FOXO4 was detected in the heart during embryonic and neonatal stages, at much lower levels than FOXO1 and FOXO3, and was not detected in the adult heart. In addition to cardiac tissue, FOXO1, FOXO3, and FOXO4 are expressed in E15 liver, brain, and forelimbs during embryogenesis. Protein expression studies confirmed expression of FOXO1 in heart tissue lysates from E14, E18, neonatal day 1 (N)1 and N7 ( Figure 1B ). The expression of phosphorylated FOXO1 (pFOXO1-Ser 256) was also examined and compared with total FOXO1 expression. Densitometric analysis of bands revealed that at E14, the level of pFOXO1 was equivalent to the level of total FOXO1. However, at E18 the ratio of pFOXO1 to total FOXO1 was decreased by 80% and continued to decline in neonatal stages. The relative increase in dephosphorylated FOXO1 is suggestive of increased nuclear localization and transcriptional activity. Thus, the expression of FOXO transcriptional targets was also examined at the protein level. Differential expression of p21 cip1 , p27 kip1 , and p57 kip2 was detected throughout the developmental time course of heart tissue lysates ( Figure 1C ). Expression of p21 cip1 and p27 kip1 protein was observed to increase at N7 and E18, respectively. In contrast, expression of p57 kip2 protein was detected in the myocardium at E14 and perinatal stages but was expressed at a much lower level at N7.
The spatial localization of FOXO and p21 cip1 protein expression was examined in the developing heart at midgestation and perinatal stages. FOXO1 protein was detected in the myocardium at E12.5 ( Figure IA in the online data supplement) and was observed to become progressively nuclear by N3 (supplemental Figure IB) . At E18.5, FOXO1 protein is predominantly localized to the nuclei of cardiomyocytes of both the trabeculae and compact layer ( Figure  2A) , consistent with increased total FOXO1 compared with pFOXO1 in immunoblot assays at this time point ( Figure 1B ). At N7, relatively fewer myocytes express FOXO1 and nuclear FOXO1 is found primarily within myocytes of the compact layer ( Figure 2B ). Quantification of FOXO1 positive nuclei revealed a peak of expression at E18 that declines in neonatal stages ( Figure 2C ). The FOXO transcriptional target p21 cip1 was predominantly expressed in trabecular myocytes at E18.5 ( Figure 2D ). In cultured cardiomyocytes, FOXO1 is found within the cytoplasm and nucleus at E14 ( Figure 2E ) and is predominantly nuclear by N1 ( Figure 2F ), where it colocalizes with p21 cip1 ( Figure 2G ). Together, these studies suggest that during the perinatal period (E18 to N3), FOXO1 protein is expressed in the heart at the proper developmental stages to direct transcriptional activation of target genes such as CKIs. Moreover, the spatial distribution of nuclear FOXO1 and p21 cip1 protein expression at E18.5 in the myocardium correlates to the previously characterized pattern of decreased cardiomyocyte proliferation in trabecular versus compact layer myocytes. 3
PI3K/AKT Signaling Affects Subcellular Localization and Phosphorylation of FOXO Factors in Embryonic Cardiomyocytes
In contrast to neonatal cardiomyocytes, primary cardiomyocytes isolated from E14.5 embryos are highly proliferative in culture (20% versus 5% by 5-bromodeoxyuridine (BrdUrd) incorporation, data not shown) and serve as a useful model to study active cardiomyocyte proliferation. Therefore the ability of the growth-promoting IGF1 and PI3K/AKT signal transduction pathway to affect FOXO transcription factors was examined in this system. To stimulate PI3K/AKT signaling, embryonic cardiomyocyte cell cultures were placed in serum-free media and then treated with IGF1. Proliferation of cardiomyocytes increased by 34% after treating the cultures with 50 ng/mL IGF1 in comparison with nontreated controls ( Figure 3A) . In contrast, treatment with LY294002, a PI3Kspecific inhibitor, decreased proliferation 56% compared with the nontreated control ( Figure 3A ). To ensure a cardiomyocyte-specific assessment of proliferation, sarcomeric myosin marker MF20 was used to identify cardiomyocytes in combination with BrdUrd immunoreactivity for DNA synthesis. Only BrdUrd ϩ /MF20 ϩ cells were counted via confocal analysis for calculation of cardiomyocyte proliferative indices ( Figure 3B ).
In multiple cell types, PI3K/AKT signaling stimulated by IGF1 regulates FOXO transcription factor function via phosphorylation and nuclear export. 25 To determine whether similar regulation of FOXO factors exists in embryonic cardiomyocytes, the subcellular distribution of FOXO1 was examined in IGF1-treated cardiomyocyte cultures. The inten- Figure 3C ). FOXO1 is phosphorylated at serine 256 in response to increased PI3K/AKT signaling and pFOXO1(Ser256) was detected in the cytoplasmic fraction of nontreated, serum-treated, and IGF1-treated cultures. However, inhibition of PI3K activity by LY294002 treatment resulted in a striking decrease in pFOXO1(Ser256) as well as increased cytoplasmic localization of FOXO1. To determine whether the inhibitory effect on FOXO1 phosphorylation was PI3Kspecific, cultures were also treated with PD98059, a mitogenactivated protein kinase-specific inhibitor, which increases the cytoplasmic localization of FOXO1 but does not inhibit FOXO1 phosphorylation at Ser256. These studies demonstrate that the proliferation of embryonic cardiomyocytes is increased by IGF1 via PI3K and that this signaling cascade promotes phosphorylation and cytoplasmic localization of FOXO1.
Recombinant adenoviruses expressing WT, DN, or CA forms of AKT were used to assess the direct effects of altered AKT function on cardiomyocyte proliferation as well as subcellular localization of FOXO1 and FOXO3. Infection of embryonic cardiomyocyte cultures with WT AKT resulted in Figure 4A ). Interestingly, CA AKT resulted in increased cytoplasmic localization of FOXO3, but not FOXO1 ( Figure 4A ). Increased WT and CA AKT resulted in a 40% to 47% increase in proliferation of cardiomyocytes, whereas DN AKT did not significantly affect proliferation in comparison with control cultures ( Figure 4B ). To examine the direct effects of altered FOXO1 activity on cardiomyocyte proliferation, WT, DN, and CA FOXO1 adenoviruses were used. Increased WT or CA FOXO1 function resulted in a 31% to 35% decrease in proliferation of cardiomyocytes ( Figure 4C ). DN FOXO1 did not significantly affect cardiomyocyte proliferation compared with control cultures ( Figure 4C ). Together, these observations provide evidence that activated AKT promotes FOXO cytoplasmic localization concomitant with increased cell proliferation in embryonic cardiomyocytes. Furthermore, increased FOXO1 function in cardiomyocytes leads to decreased cardiomyocyte proliferation, consistent with an inhibitory role in cell cycle regulation in the developing heart.
␤MHC-FOXO1 Transgenic Mice Display Aberrant Cardiomyocyte Proliferation Consistent With Altered CKI Expression
To examine FOXO1 function in cardiomyocyte proliferation in vivo, transgenes that express WT, DN, and CA FOXO1 from the ␤-MHC promoter were used for expression in cardiomyocytes beginning at E8.5 and extending throughout heart development. The WT FOXO1 transgene encodes FOXO1 protein that remains susceptible to AKT-mediated regulation via phosphorylation. In contrast, the CA FOXO1 transgene encodes a protein that cannot be phosphorylated by AKT and thus remains nuclear and able to transcriptionally activate target gene expression. The DN FOXO1 transgene encodes a truncated version of the FOXO1 protein that is capable of binding FOXO recognition sites on DNA but is not capable of transcriptional activation. Because genetic deletion of FOXO1 results in embryonic lethality at E10.5, transgenic FOXO1 founder (F 0 ) embryos were first examined at E10.5 to identify possible cardiac phenotypes. Transgene expression in the myocardium was confirmed by immunoreactivity for hemagglutinin (HA) tag linked to the ectopically expressed FOXO1 proteins (data not shown).
Increased FOXO1 function in WT and CA FOXO1 transgenic embryos resulted in embryonic lethality at E10.5 with obvious heart failure, indicated by pericardial edema, thin myocardium, and overall reduced size (nϭ13 for WT FOXO1; nϭ7 for CA FOXO1; Figure 5D and 5E). Comparable cardiovascular defects and embryonic lethality were observed in WT FOXO3 transgenic embryos at E10.5 (data not shown). Immunohistological analysis of transgenic hearts with sarcomeric myosin marker MF20 shows the gross morphological defects of the differentiated myocardium in the WT FOXO1 E10.5 transgenic hearts versus nontransgenic littermates ( Figure 5C and 5F) . The defective myocardium of WT and CA FOXO1 transgenic embryos was observed to be contractile during the initial harvest of transgenic embryos, which indicates primary differentiation of cardiomyocytes. However, the number of myocytes in the compact layer of transgenic myocardium is reduced, and there is a lack of trabeculation in these hearts, which demonstrates the reduction in myocardial growth consistent with a primary defect in cardiomyocyte proliferation. Because the ␤-MHC promoter is cardiomyocyte-specific at E10.5, the retarded growth observed in WT and CA FOXO1 transgenic embryos must be secondary to the cardiac phenotype. Interestingly, WT FOXO1 transgenic embryos exhibited a variable phenotype in that not all transgenic embryos had the defective cardiac phenotype (nϭ8/13 total embryos), whereas CA FOXO1 transgenic embryos consistently exhibited a severe hypomorphic cardiac phenotype (nϭ7/7). In contrast, all of the DN FOXO1 transgenic embryos were indistinguishable from nontransgenic littermates (nϭ5, Figure 5A and 5B) at E10.5, indicating that inhibition of FOXO1 transcriptional activity at this stage does not affect proliferation or myocardial growth.
Murine cardiomyocytes are beginning the process of cell cycle withdrawal at E18.5, thus additional DN FOXO1 transgenic embryos were generated to investigate the potential role of FOXO1 during the perinatal period. The DN Figure 6A and 6B). Histological analysis showed proper formation of ventricular chambers and interventricular septum; however, an increase in the thickness of the myocardial wall was observed in DN FOXO1 transgenic embryos in comparison with hearts of nontransgenic littermates ( Figure  6C and 6D ). Immunohistological analysis of DN FOXO1 hearts revealed an increase in the number of proliferative cardiomyocytes as measured by pHH3 immunoreactivity of cells in M phase of the cell cycle ( Figure 6E and 6F) . Thus, during the perinatal period, inhibition of FOXO function in cardiomyocytes results in abnormal growth of the myocardium and increased proliferation.
Cardiomyocyte proliferation was quantified in the defective hearts of both the E10.5 WT FOXO1 and E18.5 DN FOXO1 transgenic hearts in comparison with nontransgenic littermate controls. A significant decrease (3.3 fold, Pϭ0.017) in cardiomyocyte proliferation was observed in the E10.5 WT FOXO1 transgenic myocardium ( Figure 7A) , whereas a significant increase (2.5-fold, Pϭ0.013) was observed in the E18.5 DN FOXO1 transgenic myocardium as measured by pHH3 immunoreactivity (Figure 7C ). In the normal nontransgenic hearts, the expected decrease in cardiomyocyte proliferation was observed with 3.4% myocytes in M phase at E10.5 compared with 1.0% at E18.5. Note that mitotic indices determined by pHH3 immunoreactivity are Ϸ10-fold lower than those determined other methods, which is consistent with previous analyses in cardiomyocytes. 26 Nuclear FOXO1 also has been associated with increased apoptosis; therefore, cardiomyocyte apoptosis was measured in E10.5 WT FOXO1 and E18.5 DN FOXO1 transgenic hearts by cleaved caspase-3 immunoreactivity and TUNEL assay (data not shown). No significant differences in the number of apoptotic myocytes were observed in WT FOXO1 or DN FOXO1 transgenic embryos relative to nontransgenic littermate controls. Therefore, the cardiac phenotypes apparent in WT FOXO1 transgenic embryos at E10.5 and of DN FOXO1 embryo hearts at E18.5 are primarily attributable to altered rates of cell proliferation.
To further investigate the direct effects of altered FOXO1 function on cardiomyocyte proliferation, the expression of FOXO target genes that inhibit proliferation was examined in the hearts of FOXO1 transgenics and nontransgenic littermates at E9.75 for WT FOXO1 and E18.5 for DN FOXO1. Embryos were analyzed at E9.75 before the occurrence of obvious secondary effects on overall embryonic morphology attributable to compromised heart development. Expression of p21 cip1 and p27 kip1 cell cycle inhibitors demonstrated to be transcriptional targets of FOXO1 in cell culture, and the related gene p57 kip2 were examined. In normal hearts, p21 cip1 , p27 kip1 and p57 kip2 are expressed at very low levels at E9.75 and are increased at E18.5 when cardiomyocytes are actively withdrawing from the cell cycle ( Figure 7B and 7D) . In the E9.75 WT FOXO1 transgenic hearts, the expression of p21 cip1 , p27 kip1 , and p57 kip2 was significantly increased relative to hearts of nontransgenic littermates ( Figure 7B ). The observation that p57 kip2 expression is increased in the E9.75 WT FOXO1 embryos, coincident with increased expression of p21 cip1 and p27 kip1 , is evidence that p57 kip2 is also directly regulated by FOXO1. In striking contrast, p21 cip1 , p27 kip1 , and p57 kip2 expression was significantly decreased in the DN FOXO1 transgenic hearts at E18.5, consistent with the observed increase in cardiomyocyte proliferation at in these embryos ( Figure 7C and 7D) . Moreover, chromatin immunoprecipitation experiments confirm endogenous FOXO1 binding to p21 cip1 promoter sequences at neonatal but not embryonic stages ( Figure 7E) . Together, these studies support a key role for FOXO transcription factors in the negative regulation of cardiomyocyte proliferation through activation of cell cycle inhibitors during heart development. 
Discussion
In this report, we demonstrate that FOXO transcription factors are functionally regulated by IGF1/PI3K/AKT signaling in cultured cardiomyocytes and that altered FOXO function in vivo affects cardiomyocyte proliferation. Specifically, increased FOXO1 function at E10.5 leads to decreased cardiomyocyte proliferation, increased expression of p21 cip1 , p27 kip1 , and p57 kip2 , heart failure and embryonic death. Transgenic expression of a DN FOXO1 in cardiomyocytes at E18.5 results in thickening of the myocardium, increased cardiomyocyte proliferation and decreased expression of p21 cip1 , p27 kip1 , and p57 kip2 . Together, these analyses support a model for FOXO function in cardiomyocyte proliferation and growth (Figure 8 ). In actively proliferating cardiomyocytes, growth factors including IGF1 activate PI3K and AKT, which directly phosphorylates FOXO, leading to nuclear exclusion and inactivation. During cardiomyocyte cell cycle withdrawal, growth factor/PI3K/AKT signaling is decreased, and Previous studies have demonstrated that increased IGF1 or AKT signaling can prolong cardiomyocyte cell cycling in neonates. 1 Here we provide evidence that inhibition of FOXO function can also enhance cardiomyocyte proliferation. FOXO transcription factors can alter the expression of a spectrum of genes that cumulatively result in decreased proliferation and cell cycle arrest. 6 In established cell lines, FOXO transcription factors can activate cell cycle inhibitors, such as p130 and cyclin G2, as well as inhibit cell cycle activators including the D-type cyclins, making them powerful regulators of cell cycle progression. [27] [28] [29] The altered cardiomyocyte proliferation observed with DN FOXO1 as well as increased FOXO1 function in cultured cardiomyo- Figure 7 . Altered FOXO1 function in cardiomyocytes during heart development at E10.5 and E18.5 results in aberrant cardiomyocyte proliferation and dysregulated expression of p21 cip1 , p27 kip1 , and p57 kip2 . A, Cardiomyocyte proliferation was significantly decreased in E10.5 WT FOXO1 transgenic hearts in comparison with nontransgenic littermates as measured by percentage of pHH3 ϩ MF20 ϩ cells per total MF20 ϩ cells (nϭ3, Pϭ0.017). B, FOXO1 WT hearts displayed increased expression of p21 cip1 , p27 kip1 , and p57 kip2 at E9.75 compared with nontransgenic littermates (nϭ3), as determined by real time RT-PCR. C, Significantly increased cardiomyocyte proliferation determined by percentage of pHH3 ϩ cardiomyocytes was observed in E18.5 DN FOXO1 hearts (nϭ3, Pϭ0.013). D, Expression of p21 cip1 , p27 kip1 , and p57 kip2 was decreased in DN FOXO1 hearts compared with nontransgenic littermates at E18.5 (nϭ3), as determined by real-time RT-PCR. Significance (*) was determined by Student's t test (PϽ0.05; nϭ3). E, Chromatin immunoprecipitation was performed using chromatin from embryonic (E14) and neonatal cardiomyocytes and either FOXO1, acetyl histone H3 (positive control), or normal rabbit IgG (negative control). Precipitated DNA was then amplified by PCR using primers specific for the p21 cip1 promoter, which contains FOXO binding sites. Preferential binding of FOXO1 to the p21 cip1 promoter was observed in neonatal vs embryonic cardiomyocytes (nϭ2).
cytes and in transgenic embryos is strong evidence that cardiomyocyte cell cycle control is regulated by FOXO function.
Inhibition of FOXO function in the perinatal heart results in decreased expression of cell cycle inhibitors in the Cip/Kip family concomitant with increased cardiomyocyte cell cycling. Normally, expression of p21 cip1 and p27 kip1 increases with the decline in cardiomyocyte proliferative capacity during postnatal stages. 2 In mice lacking p27 kip1 , the cardiac cell cycle is prolonged and proliferation is extended in neonatal stages, which results in developmental hyperplasia and increased heart size. 30 However, it is important to note that eventually even the cardiomyocytes lacking p27 kip1 withdraw from the cell cycle, which indicates possible redundancy within the Cip/Kip family or other regulatory mechanisms that limit cardiomyocyte proliferation after birth. The involvement of the Cip/Kip family of CKIs in the regulation of cardiomyocyte proliferation is well documented 31 ; however, their transcriptional regulation during heart development is not well defined. Here, we show that increased FOXO1 in cardiomyocytes results in altered expression of p21 cip1 and p27 kip1 as well as p57 kip2 , which has not previously been associated with neonatal cardiomyocyte cell cycle withdrawal. In addition binding of FOXO1 protein to p21 cip1 promoter sequences was observed in neonatal but not E14 cardiomyocytes. The observations that increased cardiomyocyte cell cycling occurs in mice lacking specific CKIs and in E18.5 embryos with DN FOXO1 expression indicates that the regulation of CKIs by FOXO transcriptional activity is an important feature of neonatal cardiomyocyte cell cycle withdrawal.
In the adult heart, FOXO factors are not normally expressed, which suggests that their primary involvement in cardiomyocyte cell cycle regulation is during late heart development and neonatal cell cycle withdrawal. However, the IGF/AKT/FOXO pathway may also have important functions in adult cardiac hypertrophy and pathogenesis associated with heart disease. In support of a role for FOXO in the mature heart, loss of FOXO3 results in cardiomyocyte hypertrophy in adult mice. 9 In addition, cardiac FOXO1 protein expression is increased in human heart failure patients, which is suggestive of increased FOXO function in the diseased myocardium. 32 FOXO transcription factors also have been implicated in stem cell renewal and homeostasis in the hematopoietic lineages. 33 Therefore induction of FOXO in the adult heart could serve a related role in cardiomyocytes if mobilization of cardiac stem cells becomes a viable therapeutic avenue. Together these observations provide initial evidence for FOXO transcription factor function in cardiac hypertrophy and heart failure, but further studies are necessary to determine the precise role of FOXO function in these processes. 
